IDH2 and central nervous system cancer: In a previous study we demonstrated that TERT promoter mutations could identify among lower-grade gliomas a group of IDH-mutated-1p/19q-intact tumors with better survival and a subset of IDH wild-type tumors with worse prognosis [42].